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Abstract
Growth Hormone is essential for the regulation of growth and the homeostatic control of intermediary metabolism. GH
actions are mediated by the Growth Hormone Receptor; a member of the cytokine receptor super family that signals chiefly
through the JAK2/STAT5 pathway. Target tissue responsiveness to GH is under regulatory control to avoid excessive and off-
target effects upon GHR activation. The suppressor of cytokine signalling 2 (SOCS) is a key regulator of GHR sensitivity. This
is clearly shown in mice where the SOCS2 gene has been inactivated, which show 30–40% increase in body length, a
phenotype that is dependent on endogenous GH secretion. SOCS2 is a GH-stimulated, STAT5b-regulated gene that acts in a
negative feedback loop to downregulate GHR signalling. Since the biochemical basis for these actions is poorly understood,
we studied the molecular function of SOCS2. We demonstrated that SOCS2 is part of a multimeric complex with intrinsic
ubiquitin ligase activity. Mutational analysis shows that the interaction with Elongin B/C controls SOCS2 protein turnover
and affects its molecular activity. Increased GHR levels were observed in livers from SOCS2
2/2 mice and in the absence of
SOCS2 in in vitro experiments. We showed that SOCS2 regulates cellular GHR levels through direct ubiquitination and in a
proteasomally dependent manner. We also confirmed the importance of the SOCS-box for the proper function of SOCS2.
Finally, we identified two phosphotyrosine residues in the GHR to be responsible for the interaction with SOCS2, but only
Y487 to account for the effects of SOCS2. The demonstration that SOCS2 is an ubiquitin ligase for the GHR unveils the
molecular basis for its physiological actions.
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Introduction
Growth Hormone (GH) is a peptide hormone of 192 amino
acids secreted from the anterior pituitary [1] that plays a key role
in the regulation of intermediary metabolism and longitudinal
bone growth [2,3]. GH exerts its actions by binding to the Growth
Hormone Receptor (GHR), which is present on cell membranes in
several different organs and tissues. The GHR belongs to the
cytokine receptor super family and signals chiefly through the
Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT) pathway. Upon GH binding the GHR is tyrosine
phosphorylated by JAK2; this allows STAT5 to bind the receptor
with its Src Homology 2 (SH2) domain. Next, STAT5 is
phosphorylated by JAK2, dimerizes and migrates to the nucleus
where it induces the expression of GH-responsive genes.
One of the genes induced by GH stimulation is the suppressor
of cytokine signalling 2 (SOCS2). SOCS2 is an important negative
regulator of GHR signalling as clearly demonstrated by studies of
SOCS2
2/2 mice [4–6]. SOCS2 deficient mice show a 40%
increase in body size due to greatly enhanced postnatal growth [6].
GH-deficient, SOCS2
2/2 mice failed to show the above-described
phenotype, while treatment with exogenous GH induced excessive
growth in terms of overall body weight, body and bone lengths,
and the weight of internal organs and tissues. Microarray analysis
on liver RNA extracts after exogenous GH administration
revealed a heightened response to GH [5].
SOCS2 exerts its action through feedback inhibition of GH
signalling. GH activated STAT5b binds the promoter of SOCS2
to promote expression, in turn SOCS2 binds at least two
phosphorylated tyrosines on the GHR to negatively regulate
JAK2 and STAT5b activation [5,7]. The molecular basis for these
actions of SOCS2 are not entirely clear and two main mechanisms
of action have been proposed, one is that SOCS2 binding to the
GHR blocks the association of positive regulators [5,8–10]. The
other hypothesis is that SOCS2 is part of an ubiquitin ligase
complex targeting interacting proteins for proteasomal degrada-
tion [8,9]. Several findings indicate that this is an important part of
SOCS2 activity. SOCS2 is characterized by a SOCS-box at the C-
terminal end of the protein, similarly to other ubiquitin ligases
such as the Von Hippel-Lindau gene product (VHL) and SOCS1
[11–13]. The SOCS-box in SOCS2 interacts with Elongin B and
C as revealed by the x-ray structure of the SOCS2-Elongin B/C
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ubiquitin ligases, Cullin5, has been shown to associate with
SOCS2 [14]. Furthermore, deletions of the SOCS-box abrogate
the inhibitory actions of SOCS2 on GH induced STAT5b
activation [5]. Finally, SOCS2 was shown to be involved in the
ubiquitination and proteasomal degradation of the phosphorylated
proline-rich tyrosine kinase 2 (Pyk2) in Natural Killer cells in a
SOCS-box dependent manner [15]. Despite all the indirect
evidence, it remains undetermined whether SOCS2 actions can be
explained by ubiquitination and proteasomal degradation of the
key intracellular signalling components: GHR, JAK2 or STAT5b
or if they involve the degradation of yet unidentified regulatory
proteins. A better understanding of SOCS2 mode of action can
not only shed light on the basis for its physiological functions
related to GH but also to on other described activities related to
inflammation, mammary gland and brain development that
cannot be attributed to GH actions.
Here, we have used mutagenesis to study the influence of several
domains in the SOCS2 protein on its activity. For the first time, we
demonstrate a direct ubiquitin ligase activity of SOCS2 directed
towards the GHR. Integrity of the SH2-domain and the SOCS-
box are essential to regulate SOCS2 protein levels in mammalian
cells as well as ubiquitination activity in vitro. Accordingly, point
mutations in these domains are enough to impair the capacity of
SOCS2 to downregulate GHR levels. Our studies also reveal the
importance of tyrosine 487 on the GHR for its regulation by
SOCS2 and thus provide a mechanistic explanation for the actions
of SOCS2 on GH signalling.
Results
The interaction with Elongin B and C regulates SOCS2
turnover
Several studies have failed to find SOCS2 inhibitory activity
towards GH activated signalling pathways despite the clear
demonstration of SOCS2 activity towards GHR signalling in vivo
[16]. One possibility to explain this discrepancy is that SOCS2
associated proteins such as Elongin B and Elongin C may need to
be co-expressed with SOCS2 to achieve maximal biological
activity. Therefore, we first tested whether SOCS2 forms an
Elongin-Cullin-SOCS (ECS) complex in cells and how different
SOCS2 domains contribute to those interactions. Expression
vectors with SOCS2 cDNA containing an N-terminally located
FLAG-tag were used (Figure 1A). The expression constructs were
transfected into HEK293T cells and SOCS2 variants were
immunoprecipitated to investigate SOCS2 interacting proteins.
As shown in figure 1B, WT-SOCS2 immune precipitates were
found to contain Elongin B, Elongin C, Cullin5 and Ring-box
protein 2 (Rbx2) all of which are known to form part of the ECS
core complex (lane 2). The interactions were confirmed by mass
spectrometric analysis (data not shown). We also demonstrated
that the domain responsible for the interactions is the SOCS-box.
Within the SOCS-box we introduced two point mutations on well-
conserved residues; L163P and C167F [8]. These residues are
required for Elongin B/C binding in other SOCS-box containing
proteins [17]. We did not detect Elongin B, Elongin C, Cullin5 or
Rbx2 in the immunoprecipitates from the two point mutations or
the SOCS-box deletion mutant (SOCSDSB) (Figure 1B, lanes 5–
7). However, the three constructs with an intact SOCS-box did co-
precipitate with Elongin B, Cullin5 and Rbx2 (lanes 2–4). The
SH2-domain mutant (SOCS2SH2) and the N-terminal deletion
mutant (SOCS2DNT) did not interact with Elongin C. The reason
why the SH2-domain mutant and the N-terminal deletion mutant
fail to bind Elongin C is yet unclear. On the other hand, this is
unlikely to be an artefact, since previous data from our lab
demonstrate that a similar mutation in SOCS6 also abolishes
Elongin C binding [18].
We further examined the interaction between SOCS2 and
Elongin B/C. Experiments shown in Figure 1C demonstrate that
SOCS2 protein content in transfected cells becomes significantly
higher if Elongin C and B levels are also increased by co-
transfection. The same is true for the two mutated versions of
SOCS2 with an intact SOCS-box. As expected the protein levels
of the mutants that lack or have a mutated SOCS-box and are not
able to bind Elongin B/C are not affected by the presence of
Elongin B/C (Figure 1D).
To evaluate whether or not the increased SOCS2 level in the
presence of Elongins is a due to a folding or a degradation event
we treated transfected cells with cycloheximide to block protein
synthesis (Figure 1E). SOCS2 levels decrease faster when Elongins
B/C are not co-transfected and remain stable for a longer time in
the presence of Elongin B/C. From these experiments we
concluded that the SOCS-box is essential for the formation of
the ECS-complex and that formation stabilizes SOCS2 and
reduces its degradation.
SOCS2 displays E3 ubiquitin ligase activity in vitro
SOCS2s ability to bind to Elongin B and C, Cullin5 and Rbx2
led us to examine the functional relevance of this interaction. Since
these four proteins are known to interact with other SOCS-box
containing ubiquitin ligases [19–21], we wanted to investigate if
the SOCS2 complex has a capacity as an ubiquitin ligase.
HEK293T cells were transiently transfected with either FLAG-
SOCS2 or an empty vector in concert with Elongin B and C. Cells
were lysed and FLAG-tagged proteins were immunoprecipitated,
and the immunoprecipitates were incubated at 30uC with human
recombinant E1, UbcH5b (E2), HA-ubiquitin (Ub) and an ATP
regenerating system for 30 minutes. When analyzed with a
Western blot, high molecular weight signals corresponding to
HA-Ub covalently attached to high molecular weight protein
complexes are detected when all components of the system are
present (Figure 2A, lane 2), an indication of ubiquitin ligase
activity in the precipitates. We also assayed the activity of the
various mutated SOCS2 constructs using the above mentioned
system (Figure 2B). Our results show that the SOCS2DSB mutant
(Figure 2B, lane 4) exhibits clearly decreased ubiquitin ligase
activity as compared to the wild-type (Figure 2B, lane 2). In line
with its capacity to bind Cullin5/Rbx2, we found the SOCS2-SH2
mutant also displayed ubiquitin ligase activity, although at a lower
level when compared to the wild type variant. This is in line with
recently published data on SOCS2 where WT-SOCS2 was shown
to precipitate with ubiquitinated Pyk2 whilst SOCS2DSB only
precipitated with the un-ubiqutinated protein [15]. We thus
concluded that SOCS2 is an ubiqutin ligase and that the SOCS-
box is essential for this function.
SOCS2 regulates Growth Hormone Receptor levels
Ubiquitination is now recognized as a regulatory post-
translational modification controlling protein-protein interactions
and thereby influencing a variety of cellular processes. Given the
inhibitory role of SOCS2 in GHR signalling and since SOCS2
exhibits ubiquitin ligase activity and can bind to phosphorylated
tyrosines on the GHR [5,10], we hypothesized that SOCS2
specifically regulates GHR turnover through proteasomal degra-
dation. To test this hypothesis, we co-transfected SOCS2, Elongin
C and Elongin B expression vectors with a GHR expression vector
in HEK293T cells and analysed GHR levels by Western Blot.
Prior to lysis cells were cultivated for 4 hours in DMEM without
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Figure 3A, we detected a major band and a weaker one
corresponding to the immature GHR (GHR i; top left panel)
and after a longer exposure a band of approximately 130 kDa
corresponding to the mature, glycosylated form of the receptor
(GHR m) [22], which is present in much lower concentrations.
The expression of SOCS2 resulted in a significant reduction of
both GHR forms, even in the absence of exogenously added GH.
In contrast, cells transfected with SOCS2DSB did not differ from
control cells regarding GHR levels. The SOCS2-SH2 mutant
variant does have an effect on GHR levels but not as pronounced
as the one of WT-SOCS2.
We also examined whether the mutant versions of SOCS2 were
able to bind the receptor. As expected WT-SOCS2 and
SOCS2DSB both interact with the GHR, but as figure 3B shows
so does the SOCS2-SH2 construct although to a significantly
lesser extent. The weak interaction is still detected which suggests
that SOCS2 might be able to interact with the GHR using an
extended interface, not entirely dependent on phosphotyrosine
binding by the SH2-domain or alternatively involving a third
partner.
The interaction between WT-SOCS2 and the GHR generally
seems to be facilitated by stimulation with GH, most likely since
this leads to increased tyrosine-phosphorylation of the receptor as
Figure 1. SOCS2 forms a stable complex with Elongin B and C, Cullin 5 and Rbx2 mediated by the SOCS-box. (A) Schematic of the
various SOCS-constructs that were used. (B) Hek293T cells were transfected with Elongin B, Elongin C and Myc-Cullin5 and either an empty vector
(lane 1), wildtype (lane 2 and 8) or a mutant form of FLAG-SOCS2 (lanes 3–7) as denoted in the picture. FLAG-SOCS2 and FLAG-SOCS2 mutants were
immunoprecipitated with FLAG-beads (lanes 1–7), Mock-ip was immunoprecipitated with IgG. Western blots of immunoprecipitates and the lysate
was performed as described in the Materials and Methods. (C) and (D) Western blot of whole cell lysate from HEK293T cells transfected with FLAG-
SOCS2 and both, either or no Elongins as detailed in the figure. (E) HEK293T cells transfected with either FLAG-SOCS2 and both Elongins or FLAG-
SOCS2 alone were treated with cycloheximide (100 mg/ml) for the times indicated in the figure before lysis. C denotes the control which was
transfected with Empty vector instead of SOCS2.
doi:10.1371/journal.pone.0025358.g001
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significantly less GHR after GH stimulation. We also notice that
the SOCS2-SH2 residual GHR binding activity is also GH
stimulated. As for the reasons for this observation, we can only
speculate but its relevance is arguably minor since the amount of
GHR bound by the SOCS SH2-domain is just a minor fraction of
that bound by the WT-SOCS2. Although we cannot entirely
explain the unexpected behaviour of the SOCS2-SH2 mutant, we
can certainly conclude from these experiments that the SH2-
domain is a significant contributor to interaction of SOCS2 with
the GHR in cells.
We did not observe a truly ligand dependent decrease in GHR
levels in SOCS2 overexpressing cells (Figure 3A). Non stimulated
cells also exhibit significantly decreased levels of the receptor. This
could be related to the fact that significant amounts of GHR
tyrosine phosphorylation are observed in GH untreated cells likely
due to spontaneous dimerization and activation of GHR in the
transfected cells.
To ascertain if the decreased GHR levels observed in SOCS2
expressing cells are due to an increase in degradation, we treated
the cells with cycloheximide and examined the GHR levels in the
presence and absence of SOCS2 (Figure 3C). In the absence of
SOCS2 the levels of the mature GHR start to diminish after
approximately 2 hours whilst mature GHR levels are undetectable
after 1 hour in the presence of SOCS2 demonstrating that SOCS2
actively promotes the degradation of the mature form of the GHR.
In order to further substantiate the role of SOCS2 in the
regulation of GHR protein levels we used a previously validated
siRNA [23] to knockdown SOCS2 and examined the effect on
GHR levels. Knockdown of SOCS2 increases the levels of GHR
present in the cell, an effect that is more pronounced in the mature
GHR form. Consequently, the phosphorylation of STAT5 upon
GH treatment is increased in SOCS2 siRNA treated cells
(Figure 4A). Similar results were observed when liver from
SOCS2
2/2 mice were analyzed. The levels of GHR were also
enhanced in SOCS2
2/2 mice livers as compared to WT controls
(Figure 4B). In conclusion, in the absence of SOCS2 the mature
GHR levels and downstream GHR signalling are increased
(Figure 4A).
From these results we ascertained that SOCS2 indeed regulates
the level of GHR present in the cell and that this is an effect
dependent on a functional SOCS-box (Figure 3A). The primary
effect of SOCS2 seems to be increased degradation of the mature
signalling form of GHR (Figure 3C).
SOCS2 targets the GHR for proteasomal degradation
It has been reported earlier that the proteasome and the
ubiquitin system is involved in the endocytosis of GHR [24].
Furthermore SOCS2 has been shown to regulate the levels of Pyk2
and to increase its ubiquitination [15]. To elucidate if SOCS2
regulates GHR availability by a proteasomal pathway, we treated
cells transfected with SOCS2, Elongins and GHR with protea-
some inhibitors MG132 and Bortezomib (Figure 5A). Both
proteasome inhibitors counteracted the reducing effect of SOCS2
on receptor levels. Again, the effect is mainly noticeable for the
mature receptor. This suggests that SOCS2s regulation of GHR
levels is dependent on a functional proteasome.
To further examine the mechanism by which SOCS2 affects the
GHR we performed an in vitro ubiquitination assay with SOCS2
that had been co-precipitated with GHR. After the completion of
the ubiquitination assay, SOCS2 was eluted from the beads and
the growth hormone receptor was immunoprecipitated with a
myc-antibody and its ubiquitination level was examined by
probing with an anti HA-tag antibody. As shown in Figure 5B,
high molecular weight Myc-GHR/HA-Ubiquitin conjugates are
more abundant when SOCS2 and GHR are co-precipitated and
Figure 2. SOCS2 exhibits E3 activity in the presence of E1, E2, Ubiquitin and ATP. (A) The FLAG-tagged SOCS2-Elongin B/C complex was
immunoprecipitated from HEK293T cells transfected with FLAG-SOCS2 and Elongin B/C or Empty vector and Elongin B/C. In vitro ubiquitination assay
was performed as described in Materials and Methods except for the following: for lane 1 the assay was performed with immunoprecipitate from cells
transfected with empty vector instead of SOCS2, lane 3 lacks the E1 enzyme, lane 4 lacks the E2 enzyme, lane 5 lacks Ub, lane 6 lacks ATP. Western
blots of the samples were performed as described. (B) Immunoprecipitate from cells transfected with mutant variants of SOCS2 was used for the In
vitro ubiquitination assay. Assay was performed as described in the Materials and Methods. Cells were transfected with Elongin B/C and either Empty
vector (lane 1), FLAG-SOCS2 (lane 2) or a mutant form of FLAG-SOCS2 (lanes 3 and 4) as specified in the picture. Western blots of the samples were
performed as described.
doi:10.1371/journal.pone.0025358.g002
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(lane 2). This suggests that SOCS2 is capable of ubiquitinating
GHR in vitro and thus targeting it for proteasomal degradation.
SOCS2 effects are mediated through Tyr487 on the GHR
Since SOCS2 contains an SH2-domain capable of binding
phosphorylated tyrosines we used mutational analysis to determine
which tyrosines on the GHR are important for SOCS2s regulation
of the receptor. It has previously been reported that the SH2-
domain of SOCS2 binds to phosphopeptides corresponding to the
residues Y487 and Y595 on the GHR [5,10]. We employed four
different GHR constructs (Y487F, Y534F, Y595F and Y487/
595F) and assayed the effect of SOCS2 on the levels of these
mutant receptors (Figure 6A). The levels of two of the mutants are
clearly less affected by the presence of SOCS2; namely Y487F and
the double mutant Y487/595F. This demonstrates that tyrosine
Figure 3. SOCS2 regulates GHR levels. (A) HEK293T cells were transfected with Elongin B/C and Myc-GHR and either an Empty vector, FLAG-
SOCS2 or a SOCS2 mutant version. C denotes the control which was tranfected with FLAG-SOCS2 and Elongin B/C but not GHR. Cells were starved for
4 hours in Serum-free media prior to treatment. Next, cells were treated with GH for the times specified in the figure and subsequently lysed as
described in the Materials and Methods. Lysates were visualized by western blot. GHR was detected with an anti-Myc antibody. The immature form of
the GHR (i) is visible after a short exposure of the film (top panel) whilst the mature form (m) is visible after a longer exposure (2nd panel from the
top). (B) Co-Immunoprecipitation of GHR. HEK293T cells were transfected with Elongin B/C, FLAG-SOCS2 or a mutant version of SOCS2 together with
Myc-GHR (lanes 1,2 and 7–10) or only FLAG-SOCS2 and Elongins (lanes 5,6) or Myc-GHR alone (lanes 3,4). Cells were starved and treated with GH for 0
(2)o r1 0( +) minutes prior to lysis. Lysates were immunoprecipitated as described in the materials and methods and results visualized with western
blot. GHR was detected with an anti-Myc antibody. (C) HEK293T cells transfected with either Myc-GHR, FLAG-SOCS2 and Elongin B/C or GHR and
Elongin B/C alone were treated with cycloheximide (100 mg/ml) and GH (2 mg/ml) for the times indicated in the figure before lysis. Cell lysates were
visualized by western blot. C denotes the control which was transfected with Empty vector instead of GHR. GHR was detected with an anti-GHR
antibody.
doi:10.1371/journal.pone.0025358.g003
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regulation of GHR. This is in line with previous work from our lab
that has demonstrated that STAT5b signalling for the Y487F and
Y487/595F GHR mutants are unaffected by increasing concen-
trations of SOCS2 [5]. Surprisingly, the SOCS2 SH2-domain has
a higher affinity for peptides corresponding to phosphorylated
Tyr595 than for those containing phosphorylated Tyr487 [5] but
these differences in affinity doesn’t seem relevant for the function
of SOCS2 in the control of GHR levels.
Discussion
In this work we provide a mechanistic explanation for how
SOCS2 acts as a negative regulator of GHR signalling [5,10,25].
SOCS2 assembles a canonical ECS complex with intrinsic
ubiquitin ligase activity through interactions with Cullin5, Rbx2,
and Elongins C and B. The SOCS2 ubiquitin ligase complex has
the ability to ubiquitinate the GHR in vitro and downregulate
GHR in a proteasomally dependent manner. The downregulatory
activity of SOCS2 on the GHR is mediated by both a functional
SOCS-box and by its interaction with Tyr487 in the intracellular
domain of the GHR.
The structure of Elongin B/C in complex with the SOCS-box
domain of SOCS2, SOCS3 and VHL has been deciphered and
predict a very strong affinity between Elongin C and the SOCS-
box which has lead to the proposal that Elongin B/C interaction is
important for the correct folding and expression of the SOCS
proteins [8,26–28]. Our data showing the reduced expression of
the SOCS2 L163P and C167F SOCS-box and the R73E SH2-
domain mutants, which are defective in Elongin C interaction lend
support to these hypotheses and is in line with previous data from
studies with VHL tumour suppressor SOCS-box point mutations
[29]. However, the entire deletion of the C-terminal end of
SOCS2 (SOCS2DSB) resulted in dramatically increased levels of
SOCS2 as compared to the WT. For the SOCS-box deficient
SOCS2DSB, the stability is not influenced in any way by the
presence of the two Elongins. We can also note that its protein
level remains constantly high for all experiments. The simplest
explanation for this observation is that the SOCS2 C-terminus
also contains signals for degradation which reside outside of the
SOCS-box. A possibility is that Cullin5, whose binding motif in
SOCS2 lays outside the Elongin B/C binding domain [30]
mediates the autoubiquitination and degradation of SOCS2.
Indeed, autoubiquitination of adaptor subunits has been described
for the Vif-Elongin B/C-Cullin5 complex [31] and the structurally
related Skp-Cullin-F-box family of E3 ligases [32]. However, we
have not detected the appearance of SOCS2-ubiquitin complexes
during in vitro ubiquitination assays and further studies are needed
before a definite conclusion can be drawn.
We have demonstrated for the first time that the SOCS2
complex exhibits ubiquitin ligase activity in vitro, specifically
towards the GHR. The analysis of mutant variants of SOCS2,
confirm that SOCS2 activity is dependent on the interaction with
Elongin B/C and Cullin5/Rbx2 through its C-terminus. The
SH2-mutant showed ubiqutin ligase activity, which is in line with
the finding that this mutant retains the ability to interact with
Cullin5 and Rbx2 although it shows reduced binding to Elongin
C. This may explain the residual ubiqutin ligase activity observed
in the in vitro ubiquitination assays for this mutant since the ring
finger protein Rbx2 is considered an essential component of the
enzymatic reaction leading to the transfer of ubiquitin moieties to
the target proteins. We have also shown that overexpression of
SOCS2 downregulates GHR levels, especially the mature form of
the receptor. This downregulation is not evident when the
SOCS2DSB mutant is overexpressed, even though this mutant
retains the ability to bind to the receptor. This demonstrates that
the ability to form a complete E3 ligase complex is essential for
SOCS2 ability to regulate GHR levels. However, the SH2-domain
mutant retains both a slight ability to bind to the receptor and has
an effect on GHR levels; this suggests that the SH2-domain might
not be the only domain involved in GHR binding. The existence
of target binding motifs outside the SH2-domain has also been
demonstrated for SOCS6, where an additional interacting domain
found in the N-terminus is involved in the recognition and
ubiquitination of the p56
lck tyrosine kinase [33].
Previous publications have shown that the proteasome plays an
important role in GHR endocytosis and degradation [34]. We also
investigated the effect of proteasome inhibitors on GHR levels and
found that these counteract SOCS2 and lead to increased GHR
levels. Together with the evidence that SOCS2 is able to
ubiquitinate the GHR in vitro, it would suggest that SOCS2
mediated ubiquitination leads to endocytosis and proteasomal
degradation of the receptor. On the other hand SOCS2 is not the
only ubiquitin ligase acting on the GHR. Van Kerkhof et al. have
showed how the ubiquitin ligase ß-TrCP is involved in the
regulation of GHR endocytosis and degradation in a ligand
independent manner [35]. We have also noted in our experiments
that siRNA based ß-TrCP downregulation increase GHR levels. In
this background, SOCS2 retains its ability to downregulate GHR
levels, arguing for an independent effect of SOCS2 on GHR
turnover (data not shown). The dependency of SOCS2 mediated
downregulation on GHR Tyr487 phosphorylation, add support for
the existence of parallel pathways of GHR ubiquitination driven by
ß-TrCP and SOCS2. The fact that SOCS2 seems to preferentially
regulate mature,activatedreceptorsseem tobea crucialaspectofits
Figure 4. GHR levels increase in the absence of SOCS2. (A)
HEK293T cells were transfected with GHR and either SOCS2 or Control
siRNA. Cells were starved for 4 hours and then treated with GH for the
times indicated in the picture. Cells were subsequently lysed as
described in the Materials and Methods and lysates were visualized by
western blot. GHR was detected with an anti-GHR antibody. (B) GHR-
levels in SOCS2 KO mice. Liver lysates from SOCS2 KO mice and control
mice were visualized by western blot and analyzed for GHR levels with
an anti-GHR antibody.
doi:10.1371/journal.pone.0025358.g004
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observed in SOCS2
2/2 mice in comparison with the normal
growth rate reported for ß-TrCP1
2/2 mice [4,36].
Several studies indicate that in addition to its actions on GHR
signalling, SOCS2 also has important actions in neuron
development [37], the regulation of metabolism [38], mammary
gland development and cancer [39] as well as the immune
response [39–41]. Although it seems unlikely that the various
functions of SOCS2 are all GHR mediated, the wide tissue
distribution of SOCS2 [42] together with our demonstration that
SOCS2 controls GHR levels invite a further exploration of these
phenotypes to assess the possible role of GHR signalling. Likewise,
future studies of SOCS2 mechanisms of action should include an
assessment of its ubiquitin ligase activity as an end-point
measurement. Already, several polymorphisms of the SOCS2
gene has been identified in humans, one linked to height [43]
while the other one is linked to type 2 diabetes [44]. Our results
suggest that disorders associated to SOCS2 lack of function may
possibly be treated by GHR antagonists, one of which is already in
clinical use. This is an exiting opportunity that awaits further
validation of the role of SOCS2 in human disease.
Materials and Methods
Ethical Statement
All animal experimentations described in this work were
conducted in accordance with European and Spanish laws and
regulations (European convention 123, on the use and protection
of vertebrate mammals used in experimentation and other
scientific purposes. Spanish R.D 223/88 and O.M. 13-10-89 of
the Ministry of Agricultural, Food, and Fisheries on the protection
and use of animals in scientific research and internal biosafety and
bioethics guidelines). The study was approved by the Ethical
Committee of the University of Las Palmas de Gran Canaria, to
Professor Leandro Ferna ´ndez-Pe ´rez (project ID: MIICINN-
SAF2006-07824SAF2006).
Animal experiments
SOCS2
2/2 mice (C57BL/6J) have been described [6]. Mice
were housed under controlled temperature (23uC) and lighting
(12 hr-light and 12 hr-dark cycles) with free access to water and
food. Male SOCS2
2/2 and wild-type (WT) mice between 27–28
weeks old were allocated into groups (3–7 mice per cage) and were
fed a standard control diet. Mice were sacrificed by CO2 gas
followed by cervical dislocation. Livers were excised and snap-
frozen in liquid nitrogen before being stored at 280uC. 20–50 mg
of liver tissue was homogenized in 1mL ice-cold buffer containing:
50 mM Tris HCl pH 7.5/150 mM NaCl/5 mM EDTA/0.5%
Igepal-40/1 mM Na3VO4/20 mM NaF/1 mM dithiothretiol
(DTT)/1 mM phenylmethanesulphonylfluoride (PMSF)/16
Cocktail inhibitor (Complete mini, Roche)/16 phosphatase
inhibitor cocktail 2 (Sigma). Homogenates were cleared by
centrifugation at 14,0006g for 15 minutes at 4uC.
Cell culture
Human Embryonic Kidney cells (HEK 293T) were obtained
from the American Type Culture Collection (ATCC) and were
Figure 5. SOCS2 targets the GHR for proteasomal degradation. (A) Cells were transfected with GHR and Elongin B/C alone or in concert with
FLAG-SOCS2. C denotes the control which was transfected with FLAG-SOCS2 and Elongin B/C. Cells were starved for 2 hours then treated with the
indicated proteasomal inhibitors for 2 hours (20 mM MG132 or 5 nM Bortezomib (Bortez.)) followed by GH treatment as indicated. Cells were
subsequently lysed as described in the Materials and Methods and lysates were visualized by western blot. GHR was detected with an anti-Myc
antibody. (B) SOCS2 ubiquitinates the GHR in vitro. Cells were transfected with Elongin B/C and either Empty vector (Lane 1), FLAG-SOCS2 (Lane 5),
GHR (Lane 4) or both (Lane 2 and 3). Cells were starved, treated with 5 nM Bortezomib for 2 hours and GH for 10 min followed by lysis. After lysis
FLAG-tagged SOCS2 and proteins binding to it were immunoprecipitated with FLAG beads. In vitro Ub reaction was performed with E1/E2 (All except
lane 3), ATP-system, Ub-aldehyde, HA-Ub and normal Ub in 100 ml. After the reaction proteins were eluted from the beads with a FLAG-peptide
(100 mg/ml) and immunoprecipitated a scond time with a-Myc Ab. After IP, samples were boiled and visualized by western blot. GHR was detected
with an anti-GHR antibody. Top three panels: samples post reaction. Bottom panel: samples after second IP.
doi:10.1371/journal.pone.0025358.g005
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supplemented with 10% Foetal Bovine Serum (FBS) (Gibco),
100 U/ml penicillin and 100 mg/ml streptomycin (PAA). Cells
were grown in the presence of 5% CO2 at 37uC. Cells were lysed
in 50 mM Tris HCl, pH 7.5/150 mM NaCl/5 mM EDTA/0.5%
Igepal-40/1 mM Na3VO4/20 mM NaF/1 mM DTT/1 mM
PMSF/16Cocktail inhibitor (Complete mini, Roche). Cell debris
was removed by centrifugation at 14,0006 g for 15 minutes at
4uC. GH treatment concentration was 2 mg/ml unless otherwise
specified.
Transfection
Amounts of between 3–10 mg of plasmid DNA was used for
transfections. Transfections were carried out by employing
SuperFect (Qiagen) according to the manufacturer’s directions.
SOCS2, Elongin C and Elongin B were transfected at a 2:1:1
ratio. Samples lacking any of the components were brought to the
same amount of DNA by addition of an empty vector.
Plasmids and siRNA
Plasmids used for transfections were described earlier [5]. The
SOCS2 and GHR expression vectors were kind gifts by Prof.
Douglas Hilton and Prof. Nils Billestrup, respectively. All versions
of SOCS2 and Elongin B and C were in the pEF-BOS vector [45].
Constructs used were: FLAG-SOCS2 (SOCS2), pEF-BOS (Empty
vector), SOCS2-FLAG with a point mutation in the SH2-domain
at R73E (SOCS2SH2), FLAG- SOCS2 lacking the 37 amino acid
N-terminus (SOCS2DNT), FLAG-SOCS2 lacking the 39 amino
acid C-terminus corresponding to the SOCS-box (SOCSDSB),
FLAG-SOCS2 with a point mutation in the SOCS-box at L163P
(L163P), FLAG-SOCS2 with a point mutation in the SOCS-box
at C167F (C167F), Myc-Growth Hormone Receptor (GHR),
GHR-vectors with point mutations at Y487F (487), Y534F (534),
Y595F (595) and Y487/595F (487/595), Elongin B (Elongin B)
and Myc-Elongin C (Elongin C). 3 mg (60 mm plate) or 9 mg
(100 mm plate) of siRNA was used for knock-down experiments.
siRNA directed against SOCS2 and Control siRNA were
purchased from QIAGEN and described previously [23].
Mutagenesis
In order to introduce point mutations in the SOCS2-FLAG
construct described above the Stratagene QuikChange II Site-
directed mutagenesis kit was used according to the manufacturer’s
instructions. Two mutants were created; the L163P and the
C167F, both described above. The primers used were 59-CAT-
CAGCACCCACTCCCCAGCATTTCTGTCGAC-39,5 9-GTC-
GACAGAAATGC-TGGGGAGTGGGTGCTGATG-39,5 9-C-
CCACTCTGCAGCATTTCTTTCGACTCGCC-39 and 59-G-
GCGAGTCGAAAGAAATGCTGCAGAGTGGG-39.
Western blot
Whole cell lysates or immunoprecipitates from HEK293T cells
were separated in SDS/PAGE gels and transferred to polyviny-
lidenediflouride (PVDF) membranes (Millipore). After blotting
membranes were blocked in 5% non-fat skim milk or BSA (Sigma)
in Tris-Buffered Saline (TBS) containing 0,1% Tween 20.
Membranes were incubated with one or more of the following
antibodies as specified in the figures and figure legends; Horse-
radish peroxidase (HRP)-conjugated anti-Flag M2 (Sigma), HRP-
conjugated anti-Hemagglutinin Tag (HA) (Sigma), mouse anti-b-
actin (Santa Cruz),rabbit anti-phosphotyrosine (pY) (Cell Signal-
ing), rabbit anti-Rbx2 (Santa Cruz), goat anti-Elongin B (Santa
Cruz), goat anti-pY699-STAT5 (Cell Signaling), goat anti-STAT5
(Cell Signaling), mouse anti-Myc (Santa Cruz), mouse anti-GHR
(Santa Cruz), rabbit anti-SOCS2 (Cell Signaling) followed, when
necessary with incubation with the appropriate HRP-conjugated
secondary antibody (Santa Cruz). Membranes were visualized
with the ECL Western blotting detection system (Pierce) according
to the manufacturer’s instruction. Both SDS/PAGE and blotting
was carried out in Surelock XCell (Invitrogen).
Immunoprecipitation
HEK 293T cells were cultivated in Ø100 mm plates and
transfected with 8–10 mg of DNA as described above. Cells were
lysed in 50 mM Tris HCl, pH 7.5/150 mM NaCl/5 mM EDTA/
0.5% Igepal-40/1 mM Na3VO4/20 mM NaF/1 mM PMSF/16
Cocktail inhibitor (Roche). Lysates were centrifuged at 14,0006g
for 15 minutes at 4uC to remove cell debris. Supernatants from
identical samples were pooled and rotated with 10 ml sepharose
beads (Amersham) per sample for 1 h at 4uC to remove proteins
binding to sepharose. Samples were spun down for 2 minutes at
1000 rpm at 4uC. For immunoprecipitation with anti FLAG-
Figure 6. SOCS2 downregulation of GHR-levels is mediated by
Y487. (A) HEK293T cells were transfected with Elongin B/C, Myc-GHR or
a mutant version of the receptor alone or in concert with FLAG-SOCS2
as specified in the figure. C denotes the control which was transfected
with Empty Vector. Cells were starved for 4 hours, treated with GH for
the times indicated in the figure and lysed. Lysates were visualized by
western blot as detailed in the Materials and Methods. GHR was
detected with an anti-Myc antibody.
doi:10.1371/journal.pone.0025358.g006
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agarose beads (Sigma) per sample for 1 h at 4uC. For
immunoprecipitation with anti-Myc antibody, supernatants were
rotated with 2 mg of antibody over night at 4uC. After
supernatants had been removed the beads were washed in
Equalizing buffer; 50 mM Tris HCl, pH 7.5/150 mM NaCl/
5 mM EDTA.
In vitro ubiquitination assay
Following immunoprecipitation beads were washed three times
in HEB buffer; 20 mM Tris HCl, pH 7.5/5 mM KCl/1.5 mM
MgCl2/1 mM DTT/10 mM MG132. Beads were resuspended in
20 ml HEB buffer per sample. The packed and washed Flag-
conjugated beads containing FLAG-WT or FLAG-mutant
SOCS2 complexes were incubated with 1 ml E1 (0.5 mg/ml His6-
tagged, human recombinant, Biomol)/1.5 mlE 2( 1mg/ml His6-
tagged, human recombinant, Biomol)/8 ml 200 mM Ub/5 ml
100 mM HA-Ub/8 ml ATP regenerating system (10 mM ATP/
20 mM Tris HCl, pH 7.5/10 mM MgCl2/300 mM creatinine
phosphate (Roche)/0.5 ng/ml rabbit creatinine kinase (Calbio-
chem)) at 30uC for 30 minutes. The reaction was carried out in
HEB buffer and the total reaction volume was 100 ml. Reactions
were either stopped by the addition of 46SDS sample buffer
(Invitrogen) followed by heating to 70uC or by the addition of
20 mM EDTA. For samples stopped with EDTA, proteins bound
to the beads were eluted by a 2 hour incubation with FLAG-
peptide (100 mg/ml) followed by immunoprecipitation with anti-
Myc antibody as described above.
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